Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01336738 · ClinicalTrials.gov registry record · Phase 2

Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus

A Phase 2 study of Diabetes Type 2, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
266
Enrollment target
20
Study locations

NCT01336738: Completed Phase 2 study of Diabetes Type 2, sponsored by Pfizer.

NCT01336738 is a Phase 2 study of Diabetes Type 2 that has completed, run by Pfizer. The registered enrollment target is 266 participants, below the 656-participant average among 24 other Diabetes Type 2 trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01336738, a Phase 2 study of Diabetes Type 2, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
266 participants
Enrollment target
20
Study locations

Study Summary

B2611002 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 5 treatments for 3 months. One of the treatments will be sitagliptin which is an approved drug, and another treatment will be placebo, which does not contain active ingredient.

Primary Outcome

HbA1c is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. The normal range for the HbA1c test is between 4 percent (%) and 5.6%. HbA1c levels between 5.7% and 6.4% indicate increased risk of diabetes and levels of 6.5% or higher indicate diabetes.

Conditions Studied

Diabetes Type 2

Interventions

  • DRUG Placebo
  • DRUG 150 mg PF-04991532
  • DRUG 450 mg PF-04991532
  • DRUG 750 mg PF-04991532
  • DRUG Sitagliptin 100 mg

Study Locations (20)

Florida

  • Pfizer Investigational Site - Jacksonville
  • Pfizer Investigational Site - Melbourne
  • Pfizer Investigational Site - West Palm Beach

Arkansas

  • Pfizer Investigational Site - Jonesboro
  • Pfizer Investigational Site - Jonesboro

California

  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - Palm Springs

North Carolina

  • Pfizer Investigational Site - Cary
  • Pfizer Investigational Site - Wilmington

Rhode Island

  • Pfizer Investigational Site - East Providence
  • Pfizer Investigational Site - East Providence

Tennessee

  • Pfizer Investigational Site - Bristol
  • Pfizer Investigational Site - Kingsport

Georgia

  • Pfizer Investigational Site - Conyers

Illinois

  • Pfizer Investigational Site - Chicago

Trial Details

FieldValue
Enrollment Target 266 participants
Start Date 2011-06
Est. Completion 2012-03
Phase Phase 2
Pfizer

1,845 total trials

What the finished NCT01336738 record still lists

NCT01336738 is an interventional study that assigns participants to a tested intervention. The registered 266 participants enrollment target is mid-sized for trials with a published cap, below the 656-participant average among 24 other Diabetes Type 2 trials with a reported enrollment target (59% lower).

The record links to 1 condition, with Diabetes Type 2 appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.

NCT01336738 names 20 study sites across 13 states, led by Florida, Arkansas, California.

Frequently Asked Questions

What is clinical trial NCT01336738 about?

NCT01336738 is a clinical study titled "Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus". B2611002 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 5 treatments for 3 months. One of the treatments will be sitagliptin which is an approved drug, and another treatment will be pl...

What is the current status of trial NCT01336738?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 266 participants. The study started on 2011-06. Estimated completion is 2012-03.

What conditions does trial NCT01336738 study?

This clinical trial studies the following conditions: Diabetes Type 2.

What interventions are being tested in trial NCT01336738?

The interventions under investigation include: Placebo (DRUG), 150 mg PF-04991532 (DRUG), 450 mg PF-04991532 (DRUG), 750 mg PF-04991532 (DRUG), Sitagliptin 100 mg (DRUG).

Who is sponsoring clinical trial NCT01336738?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01336738 being conducted?

This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01336738's enrollment target sits among peer trials

266 10th of 24 higher than 15 of 24 other Diabetes Type 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05098652 · 266 participants · NA

    Coaching Dementia Caregivers to Master Care-Resistant Behavior

  • NCT06088277 · 266 participants · NA

    Texting to Reduce Human Immunodeficiency Virus (HIV) Risk

  • NCT06261814 · 266 participants · Phase 2

    Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors

  • NCT06312124 · 266 participants · NA

    A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01336738, the US trial registry maintained by the National Library of Medicine. NCT01336738 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.